In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Ascendis Pharma (ASND), with a price target of $186.00. The company’s shares closed last Monday at $103.36.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -14.6% and a 27.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aquestive Therapeutics Inc, and Allena Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ascendis Pharma with a $174.33 average price target.
See today’s analyst top recommended stocks >>
Based on Ascendis Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $66.19 million. In comparison, last year the company had a GAAP net loss of $39.51 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market.
